Interleukin (IL)‐23p19 and IL‐17 inhibitors have demonstrated high efficacy for psoriasis in randomized controlled trials, though real‐world data, particularly for risankizumab (IL‐23p19 inhibitor) and brodalumab (IL‐17 receptor (IL‐17R) inhibitor), is… Click to show full abstract
Interleukin (IL)‐23p19 and IL‐17 inhibitors have demonstrated high efficacy for psoriasis in randomized controlled trials, though real‐world data, particularly for risankizumab (IL‐23p19 inhibitor) and brodalumab (IL‐17 receptor (IL‐17R) inhibitor), is limited.
Keywords:
drug survival;
survival inhibitors;
psoriasis british;
versus biologics;
inhibitors versus;
biologics psoriasis
Journal Title: Journal of the European Academy of Dermatology and Venereology
Year Published: 2025
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of the European Academy of Dermatology and Venereology
Year Published: 2025
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!